Brief: Lavipharm Sees Non-Renewal Of Contract With PTC Therapeutics Decreasing FY 2022 Turnover By C. EUR 1.0 Million
08/07/2021 17:36
July 8 (Reuters) - Lavipharm SA LPHr.AT :
* SEES NON-RENEWAL OF CONTRACT WITH PTC THERAPEUTICS
DECREASING FY
2022 TURNOVER BY AROUND EUR 1.0 MILLION
Further company coverage: LPHr.AT
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Lavipharm SA
See all newsBrief: Lavipharm Q1 Earnings Before Tax From Continuing Operations €1.41 Million, Up 28.6% YoY
Brief: Lavipharm To Acquire Durogesic Pain Patch Rights From Janssen For $12.0 Million
Brief: Lavipharm SA FY 2025 Earnings After Tax EUR 6.0 Million Versus EUR 9.0 Million Year Ago
Brief: Lavipharm 9-Month Net Profit Down To EUR 3.5 Million
Brief: Lavipharm H1 Adjusted EBITDA At EUR 7.7 Million, Up 29.4% YoY